Links to Studies

Status Official Title Lead Investigator Last Updated
Finalised Benefit-risk of arterial thrombotic prevention with rivaroxaban for atrial fibrillation in daily clinical practice Professor Nicholas Moore 20/09/2019
Finalised Resistant Depression in France, description from the nationwide claims and hospitalization database Dr Nicholas Moore 16/09/2019
Finalised A Safety and Pharmacokinetic study in Real-life practice of Pylera® in France: The SAPHARY study Dr Patrick BLIN 25/06/2019
Finalised Malignancies in Multiple Sclerosis: multi-country cohort database studies (feasibility study) Dr Patrick Blin 01/04/2019
Finalised Observational study of post-myocardial infarction with a long follow-up Professor Nicholas Moore 19/03/2019
Finalised Assessment of Oralair® use in real-life Dr Patrick Blin 08/03/2019
Finalised Characterising the risk of major bleeding in patients with Non-Valvular Atrial Fibrillation: non-interventional study of patients taking Direct Oral Anticoagulants in the EU Dr Helga Gardarsdottir 01/03/2019
Finalised Secondary Prevention of Acute Coronary Events with Antiplatelet Agents: A cohort study in the SNIIRAM database Professor Nicholas Moore 18/02/2019
Finalised Benefit and risk of AntiThrombotic Treatments after Orthopaedic Surgery in real-life settings: a cohort study in the SNIIRAM claims and hospitalisation database Dr Patrick BLIN 15/02/2019
Finalised Study of Acute Liver Transplant-III: Prospective study of drug-exposed acute liver failure (ALF) in European liver transplant centers Professor Nicholas MOORE 31/08/2018
Finalised Follow-Up of Jevtana® in real lIfe Professor Nicholas Moore 05/06/2018
Finalised Study of Acute Liver Transplant-II Professor Sinem Ezgi Gulmez 31/08/2017
Finalised Study of Acute Liver Transplant: A study of NSAIDs-exposed acute liver failure in European transplant centres Professor Ezgi Gulmez 31/08/2017
Finalised Epidemiology of acute hepatotoxicity from medicines Professor Sinem Ezgi Gulmez 31/08/2017
Finalised Drug usage patterns of Pylera® in France using the national claims reimbursement database Professor Nicholas Moore 13/07/2017
Finalised Glargine and risk of cancer Dr Patrick Blin 30/10/2012
Ongoing Assessment of The High risk and unmEt Need in patients with coronary artery disease and type 2 diabetes in France Dr Patrick Blin 26/07/2019
Ongoing Malignancies in Multiple Sclerosis: Multi-country cohort database studies – French Study Dr Patrick Blin 26/07/2019
Ongoing Real-life anticoagulants comparative benefit-risk in nonvalvular atrial fibrillation (NVAF) in France Professor Nicholas Moore 17/07/2019
Ongoing Intravenous Iron Postauthorisation Safety Study (PASS): Evaluation of the Risk of Severe Hypersensitivity Reactions Mrs Lia Gutierrez 10/04/2019
Ongoing Nurses Internal Contamination by Antineoplastic Drugs Dr Catherine VERDUN-ESQUER 21/12/2018
Ongoing Effectiveness of Tecfidera® in multiple sclerosis: a French cohort within the nationwide claims and hospital database Dr Patrick Blin 06/12/2018
Ongoing Budget impact analysis of discontinuing Tyrosin Kinase Inhibitors in patients with chronic myeloid leukemia achieving a complete molecular response by using probabilistic Markov approach Dr Nicholas MOORE 29/11/2018
Ongoing Therapeutic strategy in metastatic castration-resistant prostate cancer: target population and changes between 2012 and 2014. Two sequential cohorts within the French nation-wide claims and hospital database Dr Patrick Blin 04/06/2018
Ongoing Real life assessment of chronic obstructive pulmonary disease Inhaler devices handling Professor Mathieu MOLIMARD 07/06/2016
Ongoing Health Outcomes, Resource Use, costs in patients with Stable coronary artery disease a cohort study in the EGB database Professor Nicholas Moore 12/02/2014
Planned Dual antiplatelet therapy for prolonged secondary prevention of acute coronary events Professor Nicholas Moore 15/07/2019
Planned Alert generation using the case-population approach in the French claims databases Dr Nicholas Moore 25/06/2019
Planned Incidence, prevalence and burden of Dry Eye diseAse in France Dr Patrick Blin 03/05/2019
Planned Use of Selincro® and impact on usual practice Professor Nicholas Moore 08/08/2017
Planned REal-life aNticoaGulants bEnefit-risk in atrial fibrilLation in France Professor Nicholas Moore 23/05/2014